SCHEMBL26969417

SCHEMBL26969417

Cc1ccc(S(=O)(=O)n2cc(Br)c3nc(C)ccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
KDM4E B2RXH2 1/20 0.43
UBE2N P61088 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
ALDH3A1 P30838 2/20 0.42
NOD1 Q9Y239 2/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 1/20 0.40
HTR6 P50406 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 2/20 0.38
MAPT P10636 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
KLK7 P49862 1/20 0.37
CYP19A1 P11511 1/20 0.37
CXCL8 P10145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26969413 0.81 KDM4E (0.44) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL26969488 0.80 L3MBTL1 (0.40) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL30443294 0.80 L3MBTL1 (0.51) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL16178874 0.78 CA1 (0.48) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL29605398 0.78 CA1 (0.50) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL31405764 0.76 L3MBTL1 (0.43) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL1891254 0.75 KDM4E (0.56) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL29414742 0.75 L3MBTL1 (0.42) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL22632588 0.75 L3MBTL1 (0.42) CA1CA2KDM4EUBE2NL3MBTL1
SCHEMBL29604813 0.73 CA1 (0.51) CA1CA2KDM4EUBE2NL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARAMCEUTICA NV (BE) 2023-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB CA1 4775/4885CA2 4577/4885KDM4E 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.